Xinrui Regenerative Completes Tens of Millions RMB Pre-A Financing Led by Sequoia China to Advance Regenerative Medicine Drug Development

VCBeat has learned that Nanjing Xinrui Regenerative Medicine Technology Co., Ltd. (“Xinrui Regenerative”) recently announced the completion of its Pre-A financing round, raising tens of millions of RMB. The round was led by Sequoia China, with participation from Dynamic Balance Capital and Haisong Medical Fund. The proceeds will be used to advance its R&D pipeline, further upgrade its new drug discovery platform, and strengthen team building.

Xinrui Regeneration was established in 2019. Leveraging its innovative “Cellular Rejuvenation” drug discovery platform, the company is dedicated to developing novel therapeutics based on principles such as in situ regeneration of tissues and organs, reversal of fibrosis, and reprogramming of tumor cells. The founding team hails from Peking University and brings 20 years of R&D experience in stem cells and regenerative medicine, having achieved internationally leading research outcomes.

Currently, the company has independently developed and established a next-generation new drug R&D technology system based on cellular phenotypes. This system includes new drug screening platforms such as high-throughput targeted transcriptome sequencing technology and machine learning technology based on cell imaging, integrated with novel technologies for iPSC differentiation and primary cell culture, advanced small-molecule target and mechanism of action (MOA) elucidation techniques, and artificial intelligence. Guided by the principle of rejuvenating and repairing/regenerating diseased cells, Xinrui Regenerative Medicine has obtained multiple lead compounds with promising translational potential.

In China, the pharmaceutical industry has entered a new phase driven by innovation. The organic integration of innovative talent, revolutionary new technologies, and investment institutions with profound professional expertise will spur the rapid development of next-generation new drug R&D enterprises.

Dr. Zhao Yang, Founder and Chief Scientist of the Company, statedXinrui Regeneration is an excellent, pragmatic, united, harmonious, and dynamic team. We have not only pioneered new avenues in in situ cellular regeneration and rejuvenation but also broken through the traditional paradigm of target-based drug discovery, establishing a comprehensively upgraded, phenotype-driven new drug development system. Moving forward, Xinrui Regeneration will continue to build and optimize AI-enhanced high-throughput, automated transcriptomics platforms, as well as more robust cell induction and new drug screening systems. We are committed to advancing our pipeline and striving to achieve R&D collaborations with other leading enterprises, universities, and research institutes, providing novel solutions for the treatment of major diseases associated with injury, aging, and pathological changes in vital organs such as the heart, liver, and kidneys. We extend our gratitude to Sequoia China, Dynamic Balance Capital, and Haisong Medical Fund for their recognition and strong support of Xinrui Regeneration’s new technologies and strategic directions. We are confident that Xinrui Regeneration will achieve continuous breakthroughs and progress in these areas, maintaining a global leadership position.

Gu Cuiping, Managing Director of Sequoia China, stated: Sequoia China has long maintained a steadfast focus on emerging technologies and early-stage enterprises, accumulating extensive investment experience and a strong track record in related medical technology fields. The field of regenerative medicine holds immense growth potential. Xinrui Regenerative Medicine already boasts an outstanding team of scientists, possesses advanced technologies and drug screening platforms, and has selected a unique path for innovative development, demonstrating strong commercial sustainability. We believe that, empowered by our shareholders and through the persistent efforts of every team member, Xinrui Regenerative Medicine will become a leading enterprise in the industry.

Zhang Xi, Business Partner of the Dongpingheng Capital Medical Team, stated: Xinrui Regeneration’s in situ somatic cell reprogramming technology fundamentally reverses organ developmental states and alters cellular transcriptional expression profiles. With nearly two decades of focused research in this field, the project team has achieved multiple pioneering results, demonstrating particular advantages in the development of novel therapeutics for diseases with complex mechanisms. Dongpingheng Capital will continue to support the R&D of innovative drugs with independent intellectual property rights, working together to build a leading enterprise in the field of regenerative medicine.

Mr. Sun Jigang, Partner at Haisong Medical Fund, stated: Xinrui Regeneration has experienced rapid growth in recent times, with its research directions offering a refreshing perspective. The scientists at Xinrui Regeneration have demonstrated courage in exploring uncharted territories despite risks, providing a novel strategy for the advancement of the biopharmaceutical sector and the treatment of related diseases. It is hoped that Xinrui Regeneration will soon become an industry benchmark, accelerating innovation within a favorable environment and making significant contributions to China’s domestic biopharmaceutical industry.

Sequoia China is committed to helping entrepreneurs build enduring, great companies by providing portfolio firms with abundant global resources and valuable historical expertise. As “entrepreneurs behind entrepreneurs,” Sequoia China focuses on investment opportunities in technology, consumer, and healthcare sectors. Over the past 17 years, Sequoia China has invested in more than 900 companies characterized by distinct technological advantages, innovative business models, high growth potential, and strong development prospects.

Dongpingheng Capital is a core enterprise of the Nanjing Jiangning Science and Technology Innovation Investment Group. It currently manages multiple government fund-of-funds, the Chinese Academy of Sciences’ Technology Transfer Fund, venture capital funds, and industry funds, covering all stages from angel investing to venture capital (VC) and private equity (PE). As a well-known early-stage professional investment institution in the industry, Dongpingheng Capital focuses on sectors such as TMT, biopharmaceuticals, high-end equipment, energy conservation and environmental protection, and new materials. The firm provides services including project investment, venture capital, project financing, investment management, strategic planning, asset restructuring, IPO facilitation, private placement financing, and related consulting. It also acts as an agent for venture capital activities on behalf of other venture capital firms, institutions, or individuals. By delivering capital services and value-added support, Dongpingheng Capital aims to accelerate the growth of startup ventures.

Haosong Medical Fund was established in 2016, with cumulative assets under management exceeding RMB 5 billion. It currently maintains offices in Beijing, Nanjing, and Suzhou. As a specialized venture capital fund under Haosong Capital, Haosong Medical Fund focuses on identifying innovative companies both domestically and internationally that possess unique advanced technologies, independent R&D capabilities, and strong market growth potential. The fund prioritizes investment opportunities in cutting-edge healthcare sectors, including biopharmaceuticals, advanced cell and gene therapies, innovative medical devices, regenerative medicine technologies, and AI-driven healthcare solutions. Its portfolio includes high-quality domestic and international projects such as EditoGene, Huadao Biotech, iRay Technology, HuiNaoYun, Wellist Therapeutics, Advenchen Laboratories, and Zymeworks (Zhimeng Bio).